Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques

Journal of Infectious Diseases

Volumn 199, Issue 3, 2009, Pages 405-413

  Kreijtz, J H C M ^a   Suezer, Y ^b   De Mutsert, G ^a   Van Den Brand, J M A ^a   Van Amerongen, G ^a   Schnierle, B S ^b   Kuiken, T ^a   Fouchier, R A M ^a   Lower J ^b   Osterhaus, A D M E ^a   Sutter, G ^b   Rimmelzwaan, G F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; MODIFIED VACCINIA VIRUS ANKARA EXPRESSING THE HEMAGGLUTININ GENE OF H5N1 INFLUENZA VIRUS A VIETNAM 1194 04 VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; IMMUNITY; IMMUNIZATION; INFLUENZA VIRUS A H5N1; LOWER RESPIRATORY TRACT; MACACA; NECROTIZING BRONCHOINTERSTITIAL PNEUMONIA; NONHUMAN; PNEUMONIA; PRIMATE; PRIORITY JOURNAL; PROTECTION; UPPER RESPIRATORY TRACT; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; BRAIN; HEMAGGLUTININS; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MACACA FASCICULARIS; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINATION, GENETIC; RESPIRATORY SYSTEM; SPLEEN; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 58849152275     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/595984     Document Type: Article

References (49)

1. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. WHO, 28 February 2008. WHO. Available at: http://www.who.int/csr/disease/avian-influenza/country/ cases-table-2008-02-28/en/index.html. Accessed 3 March 2008.
2. World Health Organization (WHO). Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as pre-pandemic vaccines. WHO, 2007. Available at: http://who.int/csr/ disease/avian-influenza/guidelines/recommendationvaccine.pdf. Accessed 8 November 2008.
3. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. Vaccination of macaques with adjuvanted formalin-inactivated influenza A (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 2008; 82:2565-9.
4. Baras B, Stittelaar KJ, Simon JH, et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 2008; 3:e1401.
5. Ninomiya A, Imai M, Tashiro M, Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007; 25:3554-60.
6. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7.
7. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
8. Kistner O, Howard MK, Spruth M, et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 2007; 25:6028-36.
9. Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005; 23:2943-52.
10. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 1999; 98:39-51; discussion 73-4.
11. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, Reichl U. Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnol Bioeng 2007; 97:73-85.
12. Nerome K, Kumihashi H, Nerome R, et al. Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model. Dev Biol Stand 1999; 98:53-63; discussion 73-4.
13. Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989; 160:191-8.
14. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003; 302:1519-22.
15. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006; 12:61-5.
16. Nwe N, He Q, Damrongwatanapokin S, et al. Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/ insect cell system significantly enhanced by suspension culture. BMC Microbiol 2006; 6:16.
17. Crawford J, Wilkinson B, Vosnesensky A, et al. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 1999; 17:2265-74.
18. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
19. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999; 73:5903-11.
20. Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43.
21. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
22. Gao W, Soloff AC, Lu X, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006; 80:1959-64.
23. Hoelscher MA, Garg S, Bangari DS, et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 2006; 367:475-81.
24. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 1999; 73:2094-8.
25. Kreijtz JH, Suezer Y, van Amerongen G, et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis 2007; 195:1598-606.
26. Mayr A, Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 1978; 41:225-34.
27. Drexler I, Staib C, Sutter G. Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 2004; 15:506-12.
28. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003; 3:263-71.
29. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998; 79:347-52.
30. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992; 89:10847-51.
31. Staib C, Drexler I, Sutter G. Construction and isolation of recombinant MVA. Methods Mol Biol 2004; 269:77-100.
32. Moss B, Carroll MW, Wyatt LS, et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996; 397:7-13.
33. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994; 12:1032-40.
34. Veits J, Römer-Oberdorfer A, Helferich D, et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 2008; 26:1688-96.
35. Sidwell RW. The mouse model of influenza virus infection. In: Zak O, Sande MA, eds. Handbook of animal models of infection: experimental models in antimicrobial therapy. San Diego, CA: Academic Press, 1999: 981-7.
36. Kuiken T, Rimmelzwaan GF, Van Amerongen G, Osterhaus AD. Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis). Vet Pathol 2003; 40:304-10.
37. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, Osterhaus AD. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 2001; 75:6687-91.
38. Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 1998; 74:57-66.
39. Palmer D, Dowle W, Coleman M, Schild G. Haemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis. Procedural guide. Atlanta: United States Department of Health and Education, 1975:25-62.
40. Frank AL, Puck J, Hughes BJ, Cate TR. Microneutralization test for influenzaAand B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 1980; 12:426-32.
41. Uiprasertkul M, Kitphati R, Puthavathana P, et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 2007; 13:708-12.
42. Uiprasertkul M, Puthavathana P, Sangsiriwut K, et al. Influenza A H5N1 replication sites in humans. Emerg Infect Dis 2005; 11:1036-41.
43. van Riel D, Munster VJ, de Wit E, et al. H5N1 virus attachment to lower respiratory tract. Science 2006; 312:399.
44. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
45. Mathews JD, McCaw CT, McVernon J, McBryde ES, McCaw JM. A biological model for influenza transmission: pandemic planning implications of asymptomatic infection and immunity. PLoS ONE 2007; 2:e1220.
46. Tellier R. Review of aerosol transmission of influenza A virus. Emerg Infect Dis 2006; 12:1657-62.
47. Stittelaar KJ, Kuiken T, de Swart RL, et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001; 19:3700-9.
48. Ramírez JC, Gherardi MM, Rodríguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000; 74:7651-5.
49. Harrop R, Connolly N, Redchenko I, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006; 12:3416-24.